echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Neurology-Autologous hematopoietic stem cell transplantation, treatment of multiple sclerosis, coexistence of efficacy and risk

    Neurology-Autologous hematopoietic stem cell transplantation, treatment of multiple sclerosis, coexistence of efficacy and risk

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, autologous stem cell transplantation (Autologous haematopoietic stem cell transplantation, AHSCT ) has been increasingly used to treat multiple sclerosis (MS) and other severe self- immune diseases, may be "reset" Based on this program The immune system and the hypothesis of stopping the inflammatory attack


    Stem Cell Immunity

    Clinical studies have shown that the activity of multiple sclerosis has been greatly inhibited and has long-term clinical stability


    In this way, Richard S Nicholas and others of UCL should check the clinical efficacy results and adverse events of the PwMS cohort treated by AHSCT in two leading centers in London, UK, according to standard clinical practice


    They conducted a retrospective cohort study of PwMS who received AHSCT treatment in two centers in London, England between 2012 and 2019.


    The cohort included 120 Pw MS; 52% had advanced MS (primary or secondary), and 48% had relapsing-remitting MS (RRMS)


    The cohort included 120 Pw MS; 52% had advanced MS (primary or secondary), and 48% had relapsing-remitting MS (RRMS)


    Epstein-Barr virus reactivation and monoclonal paraproteinemia are associated with worse PFS


    Conclusion: In this real-world cohort, the efficacy results of AHSCT are similar to those reported in the more rigorously selected clinical trial population, although the risk may be higher


    In this real-world cohort, the efficacy results of AHSCT are similar to those reported in the more rigorously selected clinical trial population, although the risk may be higher





    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.